Nestor Pharmaceuticals Limited, a active public limited company, was established on 13 October 1975 in New Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24231DL1975PLC007959. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹50.00 Cr and a paid-up capital of ₹43.18 Cr.
It upholds a compliant status. Employing 567 professional, Its leadership includes Adarsh Pal Singh (Director), Bhanu Prakash Tiwari (Director), Rahul Sehgal (Director). Past directors included Saudagar Saini, Rajiv Bedi, Adarsh Pal Singh. It holds ₹98.66 Cr open charges and ₹156.76 Cr settled loans. Its latest AGM occurred on 09 June 2025, with the balance sheet filed on 31 March 2025. It is based at G-1, Ashoka Estate 24, Barakhamba Road, New Delhi, Delhi, 110001.
U24231DL1975PLC007959
007959
13 October 1975
₹50.00 Cr
₹43.18 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Nestor Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Adarsh Pal Singh | Director | 25 May 2021 | Current |
| Bhanu Prakash Tiwari | Director | 18 Mar 2019 | Current |
| Rahul Sehgal | Director | 25 May 2018 | Current |
| Bhisham Singh | Director | 20 Feb 2023 | Current |
| Bharat Ram | Director | 25 Jan 2020 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Whole-Time Director | 31 Mar 2011 | Past |
| Pramod Abcsdd | Director | 10 Nov 2011 | Past |
| Pramod Abcsdd | Additional Director | 28 Jul 2021 | Past |
| Pramod Abcsdd | Manager | - | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2019 | Past |
| Pramod Abcsdd | Manager | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nestor Pharmaceuticals Limited, for the financial year ended 2025, experienced modest growth in revenue, with a 8.22% increase. The company also saw a substantial fall in profitability, with a 16.64% decrease in profit. The company's net worth Soared by an impressive increase of 10.78%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Nestor Pharmaceuticals had a promoter holding of 90.18% and a public holding of 9.82%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹986,600,000.00
₹1,567,582,993.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Dec 2021 | Others | ₹2.84 Cr | Open |
| 09 Dec 2021 | Others | ₹2.15 Cr | Open |
| 15 Jan 2021 | Others | ₹9.87 Cr | Open |
| 10 Nov 2010 | Others | ₹36.56 Cr | Open |
| 08 Jan 2009 | Others | ₹47.24 Cr | Open |
Explore comprehensive loan charge details -
Nestor Pharmaceuticals has a workforce of 567 employees as of Nov 20, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Nestor Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nestor Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Nestor Pharmaceuticals Limited last Annual general meeting of members was held on 09 Jun 2025 as per latest MCA records. was recorded as a recent event.
A charge with Others of Rs. 36.56 Cr registered on 10 Nov 2010 with Charge ID 10254197 was modified on 24 Apr 2025. was recorded as a recent event.
Progress on Neha Joshi was appointed as a Company Secretary was appointed as a Company Secretary on 12 Apr 2025 & has been associated with this company since 7 months 19 days . was documented.
The activity Nestor Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi. was completed.
A charge with Others of Rs. 2.15 Cr registered on 09 Dec 2021 with Charge ID 100512486 was modified on 15 Mar 2023. was recorded as a recent event.
Bhisham Singh was appointed as a Director was appointed as a Director on 20 Feb 2023 & has been associated with this company since 2 years 9 months . was recorded as a recent event.
The CIN of Nestor Pharmaceuticals Limited is U24231DL1975PLC007959.
Nestor Pharmaceuticals Limited is headquartered at G-1, Ashoka Estate 24, Barakhamba Road, New Delhi, Delhi, 110001.
Nestor Pharmaceuticals Limited was incorporated on 13 October 1975.
The current directors of Nestor Pharmaceuticals Limited are
The primary industry of Nestor Pharmaceuticals Limited is Manufacturing.
Nestor Pharmaceuticals Limited is unlisted.
The authorized capital of Nestor Pharmaceuticals Limited is ₹50.00 Cr, and the paid-up capital is ₹43.18 Cr.
The compliance status of Nestor Pharmaceuticals Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX